The mechanism of action involves binding to and activation of melanocortin receptors (primarily MC1R, MC3R, MC4R, and MC5R), which are G-protein coupled receptors expressed in various tissues including skin melanocytes, hypothalamus, and peripheral organs. Receptor engagement triggers intracellular cAMP accumulation through Gαs protein coupling, leading to activation of downstream signaling pathways that regulate melanin synthesis in melanocytes, appetite and energy expenditure in the central nervous system, and various peripheral metabolic processes. As the endogenous ligand in primates, monkey β-MSH exhibits specific receptor binding affinity and activates physiological responses involved in pigmentation, energy balance, and potentially anti-inflammatory effects, with species-specific characteristics that may differ from human or rodent counterparts.

This monkey β-MSH peptide is indicated for research use only in preclinical studies investigating primate-specific melanocortin biology, comparative endocrinology between species, and translational research using primate models. It serves as a species-specific ligand in receptor binding assays, functional cAMP assays, and in vivo studies in non-human primates to understand melanocortin signaling in pigmentation disorders, metabolic regulation, and neuroendocrine functions. The product is particularly valuable for studies requiring primate-specific reagents, bridging research from rodent models to human applications, and investigating evolutionary aspects of melanocortin system function. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.